Harry Moynihan, MD
Internal Medicine · Richmond, INNPI 1659354215
Payments from drug & device makers
Across 112 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$549
- Novo Nordisk$264
- AstraZeneca$111
- Lilly USA, LLC$71
- Novartis$70
- Amarin Pharma, Inc.$69
- plus $513 from 23 others
What the payments were for
- Food & beverage$1,647100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $549 |
| Novo Nordisk | 18 | $264 |
| AstraZeneca | 8 | $111 |
| Lilly USA, LLC | 4 | $71 |
| Novartis | 4 | $70 |
| Amarin Pharma, Inc. | 4 | $69 |
| Johnson & Johnson | 4 | $57 |
| GSK | 4 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Merck | 2 | $28 |
| Pfizer | 2 | $26 |
| Amgen | 1 | $23 |
| Inari Medical, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Bayer | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Abbott | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| VBI Vaccine (delaware) Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Philips North America LLC | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$1,647 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $82,271 |
| OzempicSemaglutide | 64 | $63,325 |
| JardianceEmpagliflozin | 59 | $42,179 |
| JanuviaSitagliptin Phosphate | 40 | $39,234 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $35,649 |
| RybelsusSemaglutide | 20 | $30,759 |
| MyrbetriqMirabegron | 31 | $19,129 |
| MounjaroTirzepatide | 17 | $17,668 |
| FarxigaDapagliflozin Propanediol | 22 | $15,928 |
| LinzessLinaclotide | 16 | $13,990 |
| XareltoRivaroxaban | 23 | $12,761 |
| EntrestoSacubitril/Valsartan | 14 | $10,706 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $9,870 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $7,916 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $7,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $264 | $94,08584 claims |
| PfizerEliquis | $26 | $82,27183 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $16 | $49,12473 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $50 | $47,03362 claims |
| MerckJanuvia | $28 | $39,23440 claims |
| Lilly USA, LLCMounjaro | $71 | $17,66817 claims |
| AstraZenecaFarxiga | $111 | $15,92822 claims |
| AbbVieLinzess | $549 | $13,99016 claims |
| Johnson & JohnsonXarelto | $57 | $12,76123 claims |
| NovartisEntresto | $70 | $10,70614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $12 | $4,12616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Richmond
- Alex GilmanRichmond$23K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.